

PROPOSED PROGRAM

THURSDAY, 24 FEBRUARY	FRIDAY, 25 FEBRUARY	SATURDAY, 26 FEBRUARY
<p>INDUSTRY BREAKFAST SYMPOSIUM (TBC) 0700 - 0845</p>	<p>INDUSTRY BREAKFAST SYMPOSIUM (TBC) 0700 - 0845</p>	<p>INDUSTRY BREAKFAST SYMPOSIUM (TBC) 0700 - 0845</p>
<p>0900 - 1000 Plenary 1 USA300 – What does the Genome Tell Us? <i>(Fred Tenover. Cepheid. The United States of America)</i></p>	<p>0900 - 1000 Plenary 2 Antibiotic Resistance Genes from the Environment <i>(Rafael Cantón. University Hospital Ramón y Cajal. Spain)</i></p>	<p>0900 - 1000 Plenary 3 The Things that Bug Me <i>(John Turnidge. SA Pathology. South Australia)</i></p>
<p>MORNING TEA AND POSTER SESSION 1 1000 - 1030</p>	<p>MORNING TEA AND POSTER SESSION 2 1000 - 1030</p>	<p>MORNING TEA 1000 - 1030</p>
<p>1030 - 1200 Symposium 1 ST93 Community MRSA – Australia’s Answer to USA300</p> <ul style="list-style-type: none"> • Origin and Epidemiology of the Species <i>(Graeme Nimmo. Queensland Pathology. Queensland)</i> • Genome and Virulence <i>(Ben Howden. Austin Health. Victoria)</i> • Public Health Response and Infection Control Interventions in the Community <i>(Keryn Christiansen. PathWest Laboratory Medicine – WA Royal Perth Hospital. Western Australia)</i> 	<p>1030 - 1200 Symposium 3 Multi Drug Resistance in the Community</p> <ul style="list-style-type: none"> • Gram Negative Resistance (CTXM) <i>(Joshua Freeman. Auckland District Health Board. New Zealand)</i> • Management of MDR Gonorrhoea <i>(Christopher Fairley. Melbourne Sexual Health Clinic. Victoria)</i> • CA-MRSA <i>(Kyra Chua. Austin Health. Victoria)</i> 	<p>1030 - 1200 Symposium 5 Emerging Antimicrobial Resistance Worldwide</p> <ul style="list-style-type: none"> • Newer Antimicrobial Agents <i>(Tim Davis. University of Western Australia. Western Australia)</i> • Scabies and Pediculosis <i>(James McCarthy. University of Queensland. Queensland)</i> • Oseltamivir and the Flu <i>(Allen Cheng. Monash Medical Centre. Victoria)</i> • Salmonella Typhi <i>(Alan Street. University of Melbourne. Victoria)</i>
<p>INDUSTRY LUNCH - TIME SYMPOSIUM (TBC) 1200 – 1400</p>	<p>INDUSTRY LUNCH - TIME SYMPOSIUM (TBC) 1200 – 1400</p>	<p>INDUSTRY LUNCH - TIME SYMPOSIUM (TBC) 1200 - 1330</p>
<p>1400 - 1530 Proffered Papers Session 1 <i>(six presentations)</i></p>	<p>1400 - 1530 Proffered Papers Session 2 <i>(six presentations)</i></p>	<p>1330 - 1500 Proffered Papers Session 3 <i>(six presentations)</i></p>
<p>AFTERNOON TEA AND POSTER SESSION 1 1530 - 1600 <i>(Authors in Attendance)</i></p>	<p>AFTERNOON TEA AND POSTER SESSION 2 1530 - 1600 <i>(Authors in Attendance)</i></p>	<p>AFTERNOON TEA 1500 - 1530</p>
<p>1600 - 1730 Symposium 2 Carbapenem Resistance in Gram Negatives: The Role of the Carbapenemases</p> <ul style="list-style-type: none"> • Mechanism and Detection <i>(Rafael Cantón. University Hospital Ramón y Cajal. Spain)</i> • Local and Overseas Epidemiology <i>(Jan Bell. SA Pathology. South Australia)</i> • Treatment and Control <i>(Thomas Gottlieb. Concord Hospital. New South Wales)</i> 	<p>1600 - 1730 Symposium 4 Clostridium difficile</p> <ul style="list-style-type: none"> • Epidemiology <i>(Tom Riley. University of Western Australia. Western Australia)</i> • Laboratory Detection – Is PCR on its Own Good Enough? <i>(Jenny Robson. Sullivan Nicolaides Pathology. Queensland)</i> • Treatment <i>(Alistair McGregor. Royal Hobart Hospital. Tasmania)</i> 	<p>1530 -1700 Workshop CLSI vs EUCAST and Beyond</p> <ul style="list-style-type: none"> • CLSI Pluses and Minuses <i>(Fred Tenover. Cepheid. The United States of America)</i> • EUCAST Pluses and Minuses <i>(Rafael Cantón. University Hospital Ramón y Cajal. Spain)</i> • What About Australia? <i>(John Turnidge. SA Pathology South Australia)</i>
<p>1730 – 1830 Annual General Meeting</p> <p>1830 – 2000 Welcome Reception</p>	<p>1800 - 1930 Industry Reception</p>	<p>1300 - 1430 Pharmacy Workshop Session 1 Changes and Controversies to Antimicrobial Use</p> <ul style="list-style-type: none"> • Practical Application to Recent Changes in Therapeutic Guidelines <i>(Tony Korman. Monash Medical Centre. Victoria)</i> • Aminoglycosides and Vancomycin Dosing – What’s In and What’s Out <i>(Verna Walroth. Peter MacCallum Cancer Centre. Victoria and Duncan McKenzie. Royal Hobart Hospital. Tasmania)</i> • Antimicrobial Dosing in Continuous Renal Replacement Therapy (CRRT) <i>(Jason Roberts. Royal Brisbane & Women’s Hospital. Queensland)</i>
		<p>AFTERNOON TEA 1430 - 1500</p>
		<p>1500 - 1630 Pharmacy Workshop Session 2 Anti-Infectives Prophylaxis</p> <ul style="list-style-type: none"> • Prophylactic Anti-Infectives in Oncology/Haematology <i>(Karin Thursky. Peter MacCallum Cancer Institute. Victoria)</i> • Antibiotic Prophylaxis in Surgery <i>(Morgyn Warner. SA Pathology. South Australia)</i> • Post Exposure Prophylaxis in HIV. <i>(Anna Pierce. Alfred Hospital. Victoria)</i>
	<p>The material in the Pharmacy Workshops (3 hours of content as Group-1 activity) has been accredited by SHPA as suitable for inclusion in an individual pharmacist’s CPD plan as outlined in the SHPA CPD program at http://cpd.shpa.org.au/scripts/cgiip.exe/WService=SHPACP/ccms.r</p> <p>The program addresses pharmacist competencies including:</p>	
	<p>Competency Unit 1.2 Practise to accepted standards</p> <p>Competency Unit 1.3 Pursue life-long professional learning and contribute to the development of others</p> <p>Competency Unit 3.1 Participate in therapeutic decision making</p> <p>Competency Unit 3.2 Provide on-going pharmaceutical management</p>	<p>Competency Unit 3.3 Promote rational drug use</p> <p>Competency Unit 4.1 Assess prescriptions</p> <p>Competency Unit 4.2 Evaluate prescribed medicines</p> <p>Competency Unit 7.2 Evaluate and synthesise information</p> <p>Competency Unit 7.3 Disseminate information</p>
<p>DISCLAIMER: This program is correct at the time of printing, but organisers reserve the right to alter the program as deemed necessary.</p>		